|
Characteristic
|
n
|
BCA cohort, n (%)
|
n
|
HER2-amplified BCA cohort, n (%)
|
|---|
|
Follow-up period for RFS (range)
| |
Mean 10.4 yr. (1 mo.-22 yr.)
| |
Mean 5.3 yr. (1 mo.-9 yr.)
|
|
Age (range)
|
308
|
Median 61 yr. (32–93 yr.)
|
177
|
Median 60 yr. (29–91 yr.)
|
|
< 50 years
| |
64 (20.8)
| |
36 (20.3)
|
|
≥ 50 years
| |
244 (79.2)
| |
141 (79.7)
|
|
HER2 status
|
308
| |
177
| |
|
Positive
| |
47 (15.3)
| |
177 (100.0)
|
|
Negative
| |
261 (84.7)
| |
0 (0.0)
|
|
ER status
|
307
| |
177
| |
|
Positive (≥10%)
| |
248 (80.8)
| |
113 (63.8)
|
|
Negative (< 10%)
| |
59 (19.2)
| |
64 (36.2)
|
|
PR status
|
307
| |
177
| |
|
Positive (≥10%)
| |
201 (65.5)
| |
74 (41.8)
|
|
Negative (< 10%)
| |
106 (34.5)
| |
103 (58.2)
|
|
Triple negativity
|
307
| |
177
| |
|
TNBC (HER2−/ER-/PR-)
| |
30 (9.8)
| |
0 (0.0)
|
|
No TNBC
| |
277 (90.2)
| |
177 (100.0)
|
|
Histological grade
|
232
| |
174
| |
|
I-II
| |
179 (77.2)
| |
41 (23.6)
|
|
III
| |
53 (22.8)
| |
133 (76.4)
|
|
Ki67 proliferation index
|
230
| |
177
| |
|
Low (< 20%)
| |
165 (71.7)
| |
33 (18.6)
|
|
High (≥20%)
| |
65 (28.3)
| |
144 (81.4)
|
|
Histological type
|
304
| |
168
| |
|
Ductal
| |
173 (56.9)
| |
156 (92.9)
|
|
Lobular
| |
131 (43.1)
| |
12 (7.1)
|
|
Tumour size
|
177
| |
142
| |
|
< 2 cm
| |
57 (32.2)
| |
68 (47.9)
|
|
≥ 2 cm
| |
120 (67.8)
| |
74 (52.1)
|
|
Tumour size
|
308
| |
172
| |
|
pT1-pT2
| |
282 (91.6)
| |
161 (93.6)
|
|
pT3-pT4
| |
26 (8.4)
| |
11 (6.4)
|
|
Lymph nodal spread
|
286
| |
169
| |
|
Positive pN+
| |
114 (39.9)
| |
73 (43.2)
|
|
Negative pN0
| |
172 (60.1)
| |
96 (56.8)
|
- Number of patient cases with available data (n) for each character is marked within the columns
